SA Business Journal: San Antonio drug developer obtains key patent approval in path to market

San Antonio-based Rapamycin Holdings Inc. has secured U.S. patent approval for the pharmaceutical formulation of its eRapa compound — a critical benchmark in the company’s growth. 

Read the full story at the San Antonio Business Journal

More Stories

Latest News

Get news to your inbox

Subscribe to receive UT Health News, a biweekly email newsletter.